To determine predictors of sustained response to inhaled nitric oxide (INO) and the financial impact of INO commercialization.
INTRODUCTION
Inhaled nitric oxide (INO) became an approved therapy for treatment of term and near-term infants with ''hypoxic respiratory failure'' in the USA at the end of 1999. This approval by the Food and Drug Administration (FDA) for use in this limited but important category of patients climaxed years of Phase II and ultimately Phase III definitive clinical trials of INO in varying doses for varying duration and for varying indications. [1] [2] [3] [4] [5] The clinically relevant outcome of the definitive clinical trials was a reduced need for extra-corporeal membrane oxygenation (ECMO) with no change in mortality, in duration of hospitalization or in the incidence of chronic lung disease. These outcomes were remarkably similar across all of the definitive Phase III studies. 6 The clinical trials did not identify which, if any, readily available clinical characteristics would predict response or lack of response to INO and subsequent emergent need for transfer to a site providing ECMO and actual initiation of ECMO. These studies also were unable to distinguish any characteristics regarding a small but important additional category of patients, those who demonstrated transient (usually <12 to 24 hours) response to INO. 7 Owing to the continuing safety issues about widespread use of INO, now that it is an approved medication, [8] [9] [10] and the limited availability of ECMO as the ultimate therapy for hypoxic respiratory failure in term infants, it is important to try to identify specific characteristics that may help physicians differentiate between infants who can be treated in a local facility and those who require immediate transfer once the diagnosis of hypoxic respiratory failure is made. In addition to this clinical uncertainty, until FDA approval it was difficult to know the financial impact that would result from the approval of INO.
There are three objectives to the present report. The first objective is to evaluate whether availability of INO has delayed initiation of ECMO in infants who still require ECMO. The second objective is to identify clinical characteristics that will allow greater precision in identifying infants responding or not responding to nitric oxide (NO). The third objective is to calculate savings, if any, in financial charges resulting from the concurrent availability of both INO and ECMO.
METHODS

Identification of Patients
We utilized data accumulated in a single referral center. Infants excluded from this analysis were those <36 weeks gestational age, those with complex congenital heart disease other than patent ductus arteriosus or patent foramen ovale; and those with congenital diaphragmatic hernia because of the documented low likelihood of improvement with INO in the immediate postbirth period. 11, 12 Infants who were deemed not eligible for ECMO by the attending neonatologist were not considered further in this analysis. Two such infants were identified. Both suffered from pulmonary hypertension associated with severe perinatal asphyxia.
General Clinical Care
All infants were treated with assisted ventilation, either with high-frequency ventilation (Sensorimedics 3100A) typically operated at 12 Hz and a mean airway pressure between 16 and 22 cmH 2 O with sufficient amplitude to achieve an arterial PCO 2 <50 mmHg. Infants could also be treated with conventional pressure limited, time cycled, continuous flow ventilation. All infants were treated with F I O 2 of 1.0. All infants had endotracheal tubes of either 3.5 or 4 mm internal diameter positioned in the upper-thoracic trachea. All infants received sedation with continuous infusion of midazolam, and were treated with dopamine or dopamine plus dobutamine to maintain mean systemic arterial pressure, directly measured through an umbilical or peripheral arterial cannula, at >40 mmHg. Muscle relaxation with vecuronium was commonly employed. All infants underwent emergent echocardiographic analysis, both to evaluate biventricular function as well as to exclude forms of congenital heart disease associated with cyanosis. All infants underwent head ultrasonographic evaluation as preparation for possible ECMO therapy.
Predictive Clinical Factors
To investigate possible relation between clinical characteristics and category of response to INO, we examined easily identifiable characteristics. These included gender, age at initiation of INO, underlying etiology of respiratory failure, and need for inotropic support for systemic blood pressure at the time of initiation. We also noted if there was any history of asphyxia or of antenatal steroid use.
Calculation of Patient Charges
Charges for ECMO therapy were calculated using the following: charges for daily ECMO physician supervision beyond the fee charged for intensive care without ECMO; room charges greater than the standard intensive care daily room rates; charges for the daily pump use and initial ECMO pump setup; pediatric surgeons' cannulation and decannulation fees; portable operating room fees for the cannulation and decannulation; and charges for the daily head ultrasound that is part of routine ECMO care. Under our current ECMO management, the only frequently performed laboratory test, in addition to these performed for standard intensive care, is a daily plasma-free hemoglobin. The only additional medication unique for ECMO use was heparin. The ECMO-specific charges for each patient so treated were calculated.
Current charges for INO are based on the charging practice used during the relevant time by INO Therapeutics (AGA Healthcare, Clinton, NJ). The daily charge is continued for a maximum of 96 hours. Any use of INO beyond this period of time accrues no additional charge for the gas, but hospital charges unique to INO continue for monitoring, calibrating equipment, and changing tanks. Use of INO for >24 hours but <96 hours is based on hourly rates. The hospital charge for INO for each patient was calculated.
Statistical Evaluation
Normally distributed continuous data were compared between groups by ANOVA followed by t-test corrected for multiple comparisons. Proportions of the groups were compared by w 2 or Fisher's exact test, as appropriate. Data are expressed as mean±SD. The estimated right ventricular systolic pressure was 59±14 mmHg at baseline. Mean systemic blood pressure was 48±7 mmHg. Distribution of underlying or associated pulmonary disorders was as follows: 25 (28%) had meconium aspiration syndrome; 20 (23%) had respiratory distress syndrome; 26 (30%) had idiopathic PPHN; 7 (8%) had pneumonia and/or shock; and 10 (11%) had other disorders.
Arterial PaO 2 for all 88 infants at baseline was 54±32 mmHg. The calculated mean (±SD) oxygenation index was 33±22. Of these 88 infants, 51 (58%) demonstrated a sustained response to initiation of INO. Mean arterial PO 2 in this group increased from 59 to 139 mmHg with a range of 40 to 240 mmHg increase. A total of 19 infants (22%) were defined as nonresponders (NR). The mean arterial PO 2 of this group changed from 49 to 54 mmHg after 2 hours of INO. A total of 18 infants (20%) were defined as transient responders.
The outcome of the infants by category is shown (Table 1) . Of the 51 SR, none needed ECMO; all survived; all were treated for more than 72 hours with INO. Of these 51 infants, 48 were weaned from INO at r1 week of treatment; all 51 were weaned from INO by 10 days. Of the NR, 19 were treated with ECMO; all survived. Of the 18 TR, 17 were treated eventually with ECMO; all but one survived. The single nonsurviving infant, who was treated with ECMO, underwent post-mortem examination, which revealed alveolar capillary dysplasia.
The duration of INO use before ECMO in the 36 ECMO-treated infants is shown in Table 2 . Of the 36 (41%) infants, 15 eventually treated with ECMO had a delay of >24 hours and 8 (22%) were delayed >48 hours. The duration of ECMO treatment ranged from 30 to 295 hours, with a mean±SD of 137±55 hours. There was no difference between outcome of infants treated with ECMO and not treated with ECMO in the duration of hospitalization or in use of supplemental O 2 at discharge (Table 3) .
Predictive Clinical Factors
Efforts were made to identify clinical characteristics differentiating SR from the other two groups. One finding was that a greater proportion of SR infants were older at the time of initiation of INO. A total of 52% of the SR were >24 hours of age when INO was initiated, compared to only 22% of the NR (p ¼ 0.012; odds ratio 0.2 with a 95% confidence interval of 0.05 to 0.69). The positive predictive value of age as a predictor of becoming an SR was 88%; the negative predictive value was 32%.
Only 16% of the NR versus 45% of the SR had PPHN as the primary diagnosis (p ¼ 0.028). Odds ratio was 4.4, with 95% confidence interval of 1.13 to 16.9. The positive predictor value is 88% with a negative predictive value of 36%. Neither mean systemic blood pressure, nor use of inotropic agents at initiation of INO was different between NR and SR groups. Mean gestational age was not different between SR and NR, nor was mean arterial PO 2 at the time of initiation of INO. There was no gender difference among groups. Only two of the 88 infants had received antenatal betamethasone administration for threatened preterm delivery. In both cases, the treatment was administered >6 weeks before actual delivery; both infants were in the SR group.
Of the 51 infants in the SR group, 47% required an increase in inotropic support by 24 hours of INO. The increased need, when present, did not correlate with improvement in arterial PO 2 . Truog et al.
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Financial Charges Current cumulative charge for a 6-day uncomplicated ECMO course is $45,700. The charge to hospitals for INO is $3000 per 24 hours period to a maximum of $12,000. Respiratory therapy charges for monitoring the treatment are added to this. Total INO charges for all 88 infants were $1,048,000. Total ECMO charges for the 36 infants treated with ECMO were $1,710,000. If all 88 patients had been treated with ECMO, the charges would have been $4,020,000. Applying the rate of ECMO usage found in the control groups of the previous trials 1-5 of 65% to our data, the total ECMO costs would be $2,605,000. If all 88 infants had been treated with ECMO, the ''savings'' would be $1,262,000 or $14,300 per patient. If 65% of the 88 had been treated with ECMO the savings would be $895,000 or $10,170 per patient. For some patients, total charges were increased as they received sustained treatment with INO and were still treated with ECMO.
DISCUSSION
Our clinical results can be summarized as follows. A total of 58% of ECMO-eligible infants demonstrated a sustained response to INO. However, 42% of the patient population failed to respond to INO, and did so over a variable period of time ranging from immediately to 48 hours following the onset of INO. Infants with idiopathic PPHN and those whose INO treatment started at >24 hours of age were more likely to respond to INO. One interpretation of this latter finding is that the disorder had been transiently stabilized with other therapies, or that the disorder was later in manifesting itself perhaps because of exacerbation of pulmonary hypertension from a postnatal event or events, and more likely to be easily reversed.
There are several implications of these clinical findings. We reconfirm the work of others that not all babies with pulmonary hypertension in the neonatal period respond to INO. [1] [2] [3] [4] 7 We also demonstrate that it is difficult to find a useful positive predictive value for success with INO based on the underlying disorder, the gestational age, or gender of the infant. We also demonstrate that an initial response to INO is not a guarantee of sustained response. The reasons for this are not clear, but may relate to borderline ''downstream'' response capacity beyond the availability of NO to induce relaxation in vascular smooth muscle lining the resistance regulating sector of the pulmonary vasculature. Since antenatal corticosteroid therapy has been shown to augment NO-induced pulmonary vasodilation, 13 we evaluated the possibility that infants previously treated as fetuses with betamethasone might respond to INO, but as only two fetuses in our group of 88 were treated, no relation was found.
If INO is used as the penultimate therapy for neonatal pulmonary hypertension, as in the current report, physicians need to be mindful that differentiating SR from NR remains very difficult. Once INO is started, even if there has been little appreciable benefit, its sudden withdrawal can be associated with severe and rapid deterioration in unstable infants. Others have demonstrated similar results. 14, 15 More sophisticated evaluation of these infants using polymorphisms for certain urea cycle enzymes 16 may differentiate such infants as potential responders or NR.
ECMO was uniformly applied to our patients during this period of time. In addition to the trial of INO prior to the initiation of ECMO, intensive support with assisted ventilation, vasopressor therapy, sedation, and in some cases alkalosis therapy had all been undertaken with no major improvement. At initiation of ECMO the mean oxygenation index was 37 and the mean alveolar-arterial (Aa) PO 2 was 620 mmHg. In the previously published trials, [1] [2] [3] [4] [5] there was no explicitly stated minimal criteria for ECMO initiation. However, overall mortality of enrollees in these studies was 13%, 6 suggesting that some infants were so critically ill that they would not be stabilized with ECMO support.
A recent estimate of the annual incidence of neonatal pulmonary hypertension in the United States 17 suggests that 7500 infants are born with pulmonary hypertension not associated with CDH per year. Approximately 33%, or 2500 infants, are treated with ECMO. Extrapolating our calculated charges and savings to this population results in approximately $26,000,000 per year in charges saved.
The calculated reduction in total financial charges by the use of INO therapy in reducing the charges for ECMO should be informed by the following considerations. Charges and costs are not the same. Although it appears that usage of ECMO is reduced, many of the fixed costs of ECMO programs would need to be continued. Indeed, the per patient costs of ECMO might increase as the fixed charges must increase to reflect overall decreased ECMO use. This change would produce a wider gap between total charges for infants who respond to INO and those who are either TR or NR, and eventually require ECMO. Thus, for some patients the availability of INO will increase the already substantial costs of care.
Other limitations of the financial analysis need to be considered. These include the fact that charges for a wide variety of therapies used by physicians in other centers prior to referral of patients to our center did not influence the need for ECMO or responsiveness to INO, but may have altered total costs of care for the infant. Walsh-Sukys et al. 17 have demonstrated previously that there is a wide variety of practice patterns for treatment of pulmonary hypertension in neonates.
It is possible that INO, when combined with other therapies (eg, selective phosphodiesterase inhibitors 18, 19 or endothelin receptor antagonists 20 ), would achieve a higher rate of success, with reduced need for ECMO. Given the current known benefit of INO, economic cost-benefit analysis should be included in clinical trials testing those combinational therapies.
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